Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Amortizatization of Intangibles (2016 - 2025)

ImmunityBio (IBRX) has disclosed Amortizatization of Intangibles for 11 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Amortizatization of Intangibles rose 7000.0% to $1.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.7 million, a 84.35% increase, with the full-year FY2025 number at $2.7 million, up 84.35% from a year prior.
  • Amortizatization of Intangibles was $1.7 million for Q4 2025 at ImmunityBio, up from $978000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $1.7 million in Q4 2025 to a low of -$5.6 million in Q4 2022.
  • A 5-year average of $132500.0 and a median of $535500.0 in 2024 define the central range for Amortizatization of Intangibles.
  • Biggest YoY gain for Amortizatization of Intangibles was 11446.15% in 2022; the steepest drop was 3842.25% in 2022.
  • ImmunityBio's Amortizatization of Intangibles stood at -$142000.0 in 2021, then plummeted by 3842.25% to -$5.6 million in 2022, then grew by 16.95% to -$4.6 million in 2023, then surged by 100.52% to $24000.0 in 2024, then surged by 7000.0% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Amortizatization of Intangibles are $1.7 million (Q4 2025), $978000.0 (Q3 2025), and $11000.0 (Q2 2025).